Alpha-fetoprotein before and after pegylated interferon therapy for predicting hepatocellular carcinoma development

doi:10.4254/wjh.v7.i19.2220

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 19

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9856)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-4) series.

Item

Count

PDF

431

WORD

296

HTML

3055

Figures (1-4)

317

Tables (1-4)

280

Sum=4379

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

585

Download

1449

Sum=2034

Publishing Process of This Article

Item

Count

Browse

1228

Download

2215

Sum=3443

Sep 8, 2015 (publication date) through Feb 21, 2025

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Hepatol. Sep 8, 2015; 7(19): 2220-2228
Published online Sep 8, 2015. doi: 10.4254/wjh.v7.i19.2220

Table 1 Characteristics of patients enrolled in the present study

Patient characteristics	n = 1255
Age (yr)	59 (18-79)¹
Gender (male/female)	674/581
HCV genotype (1/2/3)	846/406/3
White blood cell (/μL)	5076 ± 1506²
Hemoglobin (g/dL)	14.0 ± 1.5²
Platelet count (10000/μL)	16.7 ± 5.5²
Alanine aminotransferase (IU/L)	56 ± 37²
Alpha-fetoprotein (ng/mL)	4.6 (0.9-223)¹
Therapeutic outcome (SVR/relapse/NVR)	665/335/255

¹Median (range);

²Mean ± SD. SVR: Sustained virological response; NVR: Partial or null virological response.

Citation: Takeuchi Y, Ikeda F, Osawa T, Araki Y, Takaguchi K, Morimoto Y, Hashimoto N, Sakaguchi K, Sakata T, Ando M, Makino Y, Matsumura S, Takayama H, Seki H, Nanba S, Moritou Y, Yasunaka T, Ohnishi H, Takaki A, Nouso K, Iwasaki Y, Yamamoto K. Alpha-fetoprotein before and after pegylated interferon therapy for predicting hepatocellular carcinoma development. World J Hepatol 2015; 7(19): 2220-2228
URL: https://www.wjgnet.com/1948-5182/full/v7/i19/2220.htm
DOI: https://dx.doi.org/10.4254/wjh.v7.i19.2220